We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Beacon | Glaucoma | United States
Previous Study | Return to List | Next Study

Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma (Beacon)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04072016
Recruitment Status : Terminated (Significant risks (e.g., infection, endothelial cell loss) and high rate of channel plugging associated with product use.)
First Posted : August 28, 2019
Last Update Posted : January 10, 2023
Information provided by (Responsible Party):

Brief Summary:
This is a prospective, multicenter, single-arm clinical study to evaluate the safety and effectiveness of Beacon Aqueous Microshunt in patients with refractory glaucoma.

Condition or disease Intervention/treatment Phase
Glaucoma Device: Beacon Aqueous Microshunt Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Beacon Study: A Prospective, Multicenter Study to Evaluate the Safety and Effectiveness of Beacon Aqueous Microshunt for Refractory Glaucoma
Actual Study Start Date : April 29, 2020
Actual Primary Completion Date : May 16, 2022
Actual Study Completion Date : November 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: Beacon Aqueous Microshunt Device: Beacon Aqueous Microshunt
The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.

Primary Outcome Measures :
  1. Effectiveness via Intraocular Pressure Reduction [ Time Frame: 12 Months ]
    20% mean diurnal IOP reduction from baseline, on the same number or fewer topical IOP-lowering medications

  2. Safety via Serious and Adverse Event Reporting [ Time Frame: 12 Months ]
    Rate of occurrence of serious procedure-related and/or device-related adverse events.

Secondary Outcome Measures :
  1. Responder rate defined as achieving at least 20% mean diurnal IOP reduction from baseline [ Time Frame: 12 Months ]
  2. Mean Change from baseline in IOP [ Time Frame: 12 Months ]
  3. Schirmer tear test - Mean change from baseline [ Time Frame: 12 Months ]
  4. Proportion of Eyes Achieving Specific IOP Targets (≤18 mmHg, ≤17 mmHg, ≤16 mmHg, ≤15 mmHg, ≤14 mmHg, ≤13 mmHg, and ≤12 mmHg) compared to baseline [ Time Frame: 12 Months ]
  5. Number of topical IOP-lowering medications - Mean change from baseline [ Time Frame: 12 Months ]
  6. Kaplan-Meier Analysis of Failure [ Time Frame: 12 Months ]
    Glaucoma-related secondary surgical intervention with or without device explant, device explant alone, or not achieving >20% IOP reduction on the same number of medications or fewer

  7. Rate of ocular and non-ocular adverse events [ Time Frame: 12 Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 22-85 years.
  2. Refractory glaucoma: Prior failure of filtering/cilioablative procedure and/or uncontrolled IOP on maximum-tolerated medication (i.e. >=4 classes of topical lowering medications, or fewer in the case of tolerability or efficacy issues).
  3. Primary open-angle, traumatic or neovascular glaucoma.
  4. Medicated DIOP ≥20 mmHg and ≤45 mmHg on maximum-tolerated medical therapy. Note: No washout; medications stabilized 30 days prior to assessment.
  5. Baseline BCVA of light perception or better in study eye.
  6. Visual field defects consistent with glaucomatous optic nerve damage.
  7. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:

    • Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage;
    • Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or
    • Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue 8. Visual field mean deviation (MD) by Humphrey Visual Field: Visual field defects consistent with glaucomatous optic nerve damage and mean deviation worse than -3 dB in the study eye; and at least one of the following two findings:
    • A cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level on the pattern deviation (PD) plot; and/or
    • Glaucoma hemi-field test "outside normal limits".

9. At least two contiguous clock hours of intact conjunctiva near the limbus between clock hours of 9:00 and 03:00 in the study eye.

10. Adequate space in the anterior chamber by Spaeth Grade C, D or E for iris insertion (with indentation).

11. Participant has the understanding, ability, and willingness to fully comply with study procedures and postoperative care instructions.

12. Participant understands and signs the informed consent.

Exclusion Criteria:

  1. No light perception vision.
  2. Conditions of active neovascular conditions, such as active iris or corneal neovascularization, or active proliferative retinopathy in study eye.
  3. Pigmentary glaucoma in study eye.
  4. Pseudoexfoliation syndrome in study eye.
  5. Angle-closure glaucoma in study eye.
  6. Iridocorneal endothelial syndrome in study eye.
  7. Uveitic glaucoma in the study eye.
  8. Epithelial or fibrous downgrowth in the study eye.
  9. Best corrected visual acuity (BCVA) worse than 20/200 in the non-study eye.
  10. Corneal conditions in study eye inhibiting normal incisional healing (e.g. Fuch's dystrophy) or impair visualization of implant inside the anterior chamber.
  11. Prior intraocular surgery in study eye within ≤6 months before the preoperative visit (including phacoemulsification).
  12. Central corneal endothelial cell count of less than 1600 cells/mm2 in the study eye.
  13. Anticipated need for ocular surgery or retinal laser procedure in the study eye within the 12-month follow-up period.
  14. Need for glaucoma surgery combined with other ocular procedures in the study eye at time of implant (e.g. cataract surgery, penetrating keratoplasty, or retinal surgery).
  15. Unwilling to discontinue contact lens use in the study eye after surgery.
  16. Central corneal thickness ≤490μm or ≥620μm.
  17. Clinically significant inflammation or infection in the study eye within 60 days prior to the preoperative visit (e.g., blepharitis, conjunctivitis, keratitis, uveitis, herpes simplex infection) or any systemic infection. For purposes of this study, clinically significant is considered any such condition requiring prescription therapy.
  18. Any condition that prevents the device implantation in the superior region of the study eye.
  19. Vitreous in the anterior chamber for which a vitrectomy is anticipated.
  20. Functionally significant cataract in the study eye.
  21. Other clinical conditions:

    1. Poorly controlled diabetes (Type I or Type II) as determined by HbA1c >8 within 3 months of implant.
    2. Cancer requiring treatment during the duration of the study.
    3. Any drugs (e.g.: immunosuppressive drugs) or co-morbidity that might inhibit wound healing.
  22. Participation in any other clinical study during participation in this study.
  23. Engage in activities that involve submerging their head under water, such as diving or swimming.
  24. Women who are (i) pregnant, (ii) nursing, (iii) planning a pregnancy and (iv) of childbearing potential not using a reliable method of contraception.
  25. Life expectancy <1 year.

If both eyes are eligible, the eye with the worse BCVA will be selected.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04072016

Layout table for location information
United States, Colorado
Icon Eye Care
Grand Junction, Colorado, United States, 81501
United States, Minnesota
Minnesota Eye Consultants
Bloomington, Minnesota, United States, 55431
United States, Ohio
iWorks Laser and Vision Center
Dayton, Ohio, United States, 45405
Canada, Qubec
Institut de l'oeil des Laurentides
Boisbriand, Qubec, Canada, J7H 0E8
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: MicroOptx
ClinicalTrials.gov Identifier: NCT04072016    
Other Study ID Numbers: 4046
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: January 10, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Ocular Hypertension
Eye Diseases